cyrilzakka/clinical-trials huggingface dataset:
Optimization of Chest Tube Drainage Management

Early recovery after surgery was new developing science in recent years. However , there was few reports in thoracic surgery field . Investigators try to using digital chest drainage management system into the field of postoperative care and to see whether it could help patients to recovery from surgery as soon as possible. According to investigators's clinical data collecting , investigators will establish a new postoperative care guideline for those patients who receive thoracic surgery

Drainage of the space between the ribs and lungs has been practiced since the time of Hippocrates. Thus far, the function of chest tubes, specifically to drain fluid or air from the pleural space, has virtually remained unchanged for more than 3000 years. The use of chest drainage tubes after thoracic surgery is crucial to evacuate air leakage and/or pleural effusion; however, delayed tube removal may exacerbate pain, delay recovery of lung function and prolong hospitalization. Recently, Thopaz digitally monitored thoracic drainage system (Medela Healthcare, Baar, Switzerland)has been designed to provide objective measurements of air leakage and pleural pressure. With this system, air leakage and pleural pressure can be accurately measured in mL/min and mm H2O, respectively. The rate of air leakage can be seen on a display in real time. Digital surveillance for air leakage is reported to reduce interobserver disagreement in decision making in the management of patients with chest tubes, which might help caregiver a more solid evidence of strategies of postoperative chest drainage care.

Eligibility Criteria:
Inclusion Criteria:

* Volunteer to join the study after thoroughly explanations
* Patient who received thoracoscope surgery for lung lesion

Exclusion Criteria:

* Not willing to join the study after thoroughly explanations
* Patients who have not received thoracoscope surgery for lung lesion
Smart mHealth Strategy for Physical Activity and Health Promotion

The purpose of this study is to develop a Smart mHealth Strategy that delivers behavior change techniques through wearable physical activity trackers and social media chatbots, including self-monitoring, real-time feedback and reminders, goal-setting, competition and rewards, social support, and health coaching. This study also aims to explore the effect of the Smart mHealth Strategy on the behavioral outcomes and psychological factors of physical activity, and physical and mental health. The study design is a three-stage randomized controlled trial. In each stage, 120 are recruited and randomly assigned to control and experimental groups. Participants are adults with insufficient physical activity and a sedentary lifestyle. The Smart mHealth Strategy uses smartwatches and self-developed chatbots. The constrained dialogue content is designed to finally deliver the six behavior change techniques. Data are collected in the pre-, mid-, and post-tests. The measurement includes self-administered questionnaires, Actigraphy GT9X, Inbody 270S, OMRON HEM-7130, and heart rate variability monitors.


Eligibility Criteria:
Inclusion Criteria:

Adults who is the age of majority, with insufficient physical activity, and a sedentary lifestyle who have smartphones

Exclusion Criteria:

* Individuals' health conditions may affect physical activity in daily living and the experiment, such as disability, serious health problems

  * There are unconventional life plans during the experiment, such as going abroad for vacation, pregnancy, and surgery.

    * Individuals have using experiences in any wearable physical activity trackers in the past six months ④ People who have ever had severe allergies to any wearable device ⑤ Professional athletes or student-athletes
Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids

The objective of the research is to study the expression of the ACE 2 receptor and the TMPRSS2 serine protease in the tonsils and adenoids of children and adults.

The entry point for SARS-CoV-2 into the body is the nasal and pharyngeal mucosa. Angiotensin-converting enzyme 2 (ACE 2) was quickly identified as the functional receptor for SARS-CoV-2. Furthermore, the TMPRSS2 serine protease is required for the anchoring of the S protein in cell lines. In addition, the most commonly used screening test is a test for viral RNA by RT-PCR on a nasopharyngeal sample because the viral load is high.

The tonsils and adenoids could be a target organ of the virus. In order to study this hypothesis, the expression of ACE 2 and the serine protease TMPRSS2 will be sought in these tissues.

In addition, children, generally at high risk of severe viral respiratory infections (RSV, influenza), have milder symptoms than older patients with SARS-CoV-2 infection. The reason for this difference remains elusive. But one of the hypotheses formulated is that the level of expression of ACE 2 and / or TMPRSS2 may differ between adults and children, the viral load seeming to be correlated with the severity of the attack. In order to study this hypothesis, we will therefore compare the level of expression of ACE 2 in the tonsil tissue of children and adults.

Eligibility Criteria:
Inclusion Criteria:

* Children and adults, without SARS-CoV-2 infection, in whom an adenoidectomy and/or tonsillectomy is performed for their care in the hospitals of Assistance Publique-Hôpitaux de Paris participating in the study.
* Holders of parental authority of minor patients and adult patients not opposed to participation in the study.

Exclusion Criteria:

- N/A
Pilot Brief Communal Coping Intervention for Adults With Type 1 Diabetes

We plan to develop a communal coping intervention aimed at instilling a shared appraisal of diabetes and increasing patient-partner collaboration. To that end, we will pilot the first randomized clinical trial of a brief communal coping intervention among couples in which one person has T1D

We will recruit 66 couples in which one person has type 1 diabetes. Power is based on effect sizes from previous couple intervention studies and meta-analyses on primary outcomes. Couples will be randomly assigned to either a communal coping intervention or an attention (diabetes education) control group. All couples will come to the laboratory or meet via zoom, complete a baseline questionnaire assessment (primary and secondary outcomes, mediators) and have a videotaped conversation about how they cope with diabetes. The intervention group will receive the communal coping intervention. Couples in the intervention group will identify 5 collaborative implementation intentions, whereas controls will identify 5 individual implementation intentions. After the in-person session, couples will individually complete a daily diary at the end of the day for 14 consecutive days which focuses on daily communication, mood, and patient self-care. During the first 7 days, the intervention group will receive two text messages per day (morning focus on shared appraisal, evening focus on one of collaborative implementation intentions identified during in-person session). An in-person follow-up interview will take place 6 weeks after the initial session, during which primary outcomes, secondary outcomes, and mediators will be assessed and the videotaped conversation repeated.

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of type 1 diabetes for at least one year

  * married or living with someone for at least one year who is willing to participate in the study as the study partner
  * age 18 and over
  * reliable access to the internet at home

Exclusion Criteria:

* Non-English speakers
* Patient has a major chronic illness that affects daily life more than diabetes (e.g., currently undergoing treatment for cancer)
* Partner does not consent to participate in study
* Partner has diabetes
A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

The primary goal was to describe the safety of the investigational product when given monthly to prevent serious respiratory infection among children with significant heart disease.

The primary objective was to describe the safety and tolerability of motavizumab when given monthly as prophylaxis against serious RSV infection among children with hemodynamically significant congenital heart disease.

Eligibility Criteria:
Inclusion Criteria:

* 24 months of age or younger at randomization (child must have been randomized on or before their 24-month birthday)
* Documented, hemodynamically significant CHD
* Unoperated or partially corrected CHD
* Written informed consent obtained from the patient's parent(s)/legal guardian(s) Note: The following children were not eligible: children with uncomplicated small atrial or ventricular septal defects or patent ductus arteriosus, children with aortic stenosis, pulmonic stenosis, or coarctation of the aorta alone. Children with acyanotic cardiac lesions must have pulmonary hypertension \[≥ 40 mmHg measured pressure in the pulmonary artery (PA)\] or the need for daily medication to manage CHD.

Exclusion Criteria:

* Unstable cardiac or respiratory status, including cardiac defects so severe that survival was not expected or for which cardiac transplantation was planned or anticipated
* Hospitalization, unless discharge was anticipated within 21 days
* Anticipated cardiac surgery within two weeks of randomization
* Requirement for mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure or other mechanical respiratory or cardiac support
* Associated non-cardiac anomalies or end organ dysfunction resulting in anticipated survival of less than six months or unstable abnormalities of end organ function
* Acute respiratory illness, or other acute infection or illness Note: children with any respiratory symptoms must have had a negative RSV test prior to randomization
* Chronic seizure or evolving or unstable neurologic disorder
* Known immunodeficiency
* Mother with HIV infection (unless the child had been proven to be not infected)
* Known allergy to Ig products
* Receipt of any polyclonal antibody (for example, Hepatitis B IG, IVIG, VZIG) within 3 months prior to randomization
* Receipt of palivizumab (Synagis®) within 3 months prior to randomization
* Use of investigational agents within the past three months (other than investigational agents commonly used during cardiac surgery or the immediate post-operative period, e.g., nitric oxide)
* Current participation in other investigational protocols of drugs or biological agents
* Previous participation in MI-CP124 (Season 1)
Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels

Particpants were divided into groups based on doses of rosuvastatin and were assessed and for CPK, LDL and AST levels


Eligibility Criteria:
Inclusion Criteria:

patients who were already on statins

Exclusion Criteria:

hereditary diseases including familial hypercholesterolemia and kidney diseases
Detection of Group A β-Hemolytic Streptococci in Oral Samples

This prospective, sample collection study will assess different oral and/or nasal sample types collected from patients suspected of suffering from GABHS pharyngitis to conduct research and development on innovative GABHS detection methods specific for each sample type.

Study candidates are patients age 3 and older with complaints of sore throat and are suspected of suffering from GABHS pharyngitis. Patients who consent and are found eligible will be enrolled in the study. Subjects will be tested according to the conventional standard of care in addition to providing extra specimen samples for the study.

After each patient has been tested according to conventional SOC and has enrolled in the study, up to ten oral and/or nasal specimen samples will be collected . Study participation is complete once all specimen samples are collected.

Most or all collected samples will be qualitatively tested and may also be quantitatively and/or semi-quantitatively tested for the presence of GABHS. Some collected samples may additionally or alternatively be tested for other respiratory infections as well. (such as SARS-CoV-2, influenza, etc.)

Eligibility Criteria:
Inclusion Criteria:

1. Patient, either male or female, is age 3 years or older;
2. Patient is suspected of suffering from GABHS pharyngitis, and is prescribed a throat culture by conventional SOC;
3. Patient or legal guardian is able to communicate with study personnel;
4. Patient or legal guardian is able to understand oral and written information regarding the nature of the study and is willing to provide written informed consent.

Exclusion Criteria:

1. Patients presently on antibiotics prescribed by a physician for treatment or prevention of GAS infection or has taken antibiotics within the past 3 days ( unless patient only first started taking antibiotics within the past 24 hour)
2. pregnancy
3. Patients who took mouth rinse or taking oral treatment for mouth sores within 3 hours of study
Multinational Survey of Epidemiology, Morbidity, and Outcomes in Intracerebral Hemorrhage

The aim of this project is development of a comprehensive, prospective, multinational, multicenter, hospital-based, data repository for patients with intracerebral hemorrhage.

MNEMONICH is a disease-specific registry of prospectively collected data obtained from the integration and harmonization of preexisting single-center data sets. It was formed to provide clinician-scientists around the world a comprehensive database to direct future studies toward better understanding of ICH. MNEMONICH will help examine global variability in the prevalence of ICH and identify research priorities.

New data for MNEMONICH will be prospectively collected on a wide range of features including demographics, medical history, dates and times of symptom onset, presentation symptoms, hemodynamic signs, initial and chronic medical therapy, diagnostic imaging, laboratory and genetic analyses, pathological data, and surgical and medical management. Future research will be based upon ad hoc analysis of this data.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of spontaneous intracerebral hemorrhage (ICH) met by clinical and imaging criteria
* Age 18 and above
* Able to consent

Exclusion Criteria:

* ICH due to trauma
* ICH due to vascular malformation or aneurysm
* ICH due to brain tumor
* ICH due to underlying infectious lesion (e.g., abscess)
Reporting of Adverse Events in Patients Treated With New Oral Anticoagulants

Serious adverse events in patients treated with new oral anticoagulants are underreported.

The study investigates if serious adverse events in patients treated with NOAC are reported to the Health and Medicines Authority.

Eligibility Criteria:
Inclusion Criteria:

* patients admitted for GI bleeding while in treatment with NOAC

Exclusion Criteria:

* none
Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury

The purpose of the study is to evaluate whether FX06 is capable of limiting infarct size following balloon catheterization for acute myocardial infarction.


Eligibility Criteria:
Inclusion Criteria:

* Patients who have given informed consent
* Patients after primary percutaneous coronary intervention (PCI) for acute ST-elevation myocardial infarction (STEMI)
* Men or women with no child bearing potential
* Onset of symptoms to balloon time \< 6 hours
* ST-elevation of at least 2 mm in at least 3 leads on 12-lead electrocardiogram (ECG)
* Primary PCI indicated per standard of care
* First myocardial infarction (MI)
* Single index lesion with complete occlusion \[thrombolysis in myocardial infarction (TIMI) flow 0/I\] of one target vessel.

Exclusion Criteria:

* History of MI (from patient history, or from ECG)
* Chest pain or other angina symptoms in the 24 hours before the first recognized symptoms of the acute myocardial infarction (AMI)
* Need for coronary artery bypass graft (CABG)
* Administration of any thrombolytic agent since onset of AMI symptoms
* Serious procedural complications (e.g., procedural unintended occlusion of coronary artery branch, cardiac tamponade, emergency bypass operation, LM dissection, etc.)
* Presence of cardiogenic shock: hemodynamically unstable and/or need for positive inotropic agents
* Contraindication to cardiovascular magnetic resonance (CMR): claustrophobia, pacemakers, defibrillators and other electronic devices, and metallic cerebral clips; frequent extrasystoles (\> 12/Min) or atrial fibrillation (AF).
* Known renal dysfunction defined as serum creatinine \> 250 µmol/l
* Previous CABG
* History of congestive heart failure (CHF)
* Body mass index (BMI) \> 35
* Patients who cannot communicate reliably with the investigator
* Patients who are unlikely to cooperate with the requirements of the study
* Patients who are unwilling and/or unable to give informed consent
* Patients at increased risk of death from a pre-existing concurrent illness
* Patients participating in another clinical study
* Patients who have used any other investigational drugs within 1 month of first dosing
* Patients who have participated already in this study
* Patients who are employees at the investigational site; relatives or spouse of the investigator.
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects

Levosimendan and its prolonged active metabolite, OR-1896, have been shown to have favorable hemodynamic effects in subjects with pulmonary hypertension and right heart failure. Clinical studies that have been conducted in subjects with right heart failure and pulmonary hypertension suggest levosimendan may be an effective therapy in treatment of subjects with PH-HFpEF. This study will provide demonstration of levosimendan/OR-1896's effectiveness in critical measures of hemodynamic response in weekly administration of levosimendan and the concomitant response as measured by exercise capacity, subject quality of life, and changes in functional capacity. These data will support and guide the Phase 3 development of levosimendan in PH-HFpEF subjects.

Eligibility Criteria:
Inclusion Criteria:

Criteria to enter Open-label, Lead-in Dose Phase:

* Diagnosis of World Health Organization (WHO) Group 2 Pulmonary Hypertension (PH) with Heart Failure with Preserved Ejection Fraction (HFpEF) confirmed at the time of the diagnosis of pulmonary hypertension.
* Baseline Pulmonary Arterial Pressure (PAP) ≥35, Pulmonary Capillary Wedge Pressure (PCWP) ≥20, New York Heart Association (NYHA) Class IIb/III, Left Ventricular Ejection Fraction (LVEF) ≥40%
* Ability to walk at least 50 meters, but not more than 550 meters in a six-minute walk test.
* Stable oxygen treatment (if applicable), and medications for heart failure, hypertension, and respiratory condition

Criterion for Randomization to Double-blind Phase:

* Response to Open-label, Lead-in Levosimendan: Patients who demonstrate a ≥4mmHg reduction in PCWP from baseline measured at bicycle exercise (25 watts) with no more than a 10% decrease from baseline in cardiac index

Exclusion Criteria:

* Subject has a primary diagnosis of PH other than Group 2 PH-HFpEF
* Previous Percutaneous Coronary Intervention (PCI) or cardiac surgery (CABG), unless they have a negative stress test in the last 12 months)
* Congenital heart disease
* Clinically significant lung disease
* Planned heart or lung surgery
* Cardiac Index \>4.0 L/min/m2
* Concomitant administration of pulmonary vasodilator therapy or taken within 14 days
* Dialysis or Glomerular Filtration Rate (GFR) \<30 mL/min/1.73 m2
* Liver dysfunction with Child-Pugh Class B or C
* Evidence of systemic infection
* Weight \> 150kg
* Symptomatic systolic blood pressure (SBP) cannot be managed to ensure SBP \>100 mmHg
* Heart rate \>= 100 bpm with the study drug, symptomatic and persistent for at least 10 minutes
* Hemoglobin \< 80 g/L
* Serum potassium \< 3.0 mmol/L or \> 5.5 mmol/L at baseline
* Patients having severely compromised immune function
* Pregnant, suspected to be pregnant, or breast-feeding
Biomarker Analysis of HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With Peritoneal Metastasis

A single-center, observational study, integrated biomarker analysis of HIPEC combined Programmed cell death 1 /Programmed cell death 1 ligand 1(PD1/PDL1)inhibitor in previously treated patients of advanced gastric cancer with peritoneal metastasis. Tests will be performed on tumor tissue and blood samples, and imaging assessments will be reviewed in order to monitor how well each patient responds to treatment. This is an observational study, so participants will not receive cancer treatment, other than the treatment received as standard of care.

To analyze the correlation between genomic alterations, gene expression characteristics and the efficacy of HIPEC combined with PD1/PDL1 inhibitor conversion therapy in patients with peritoneal metastasis of gastric cancer. Circulating tumor DNA(ctDNA) in plasma samples and DNA, RNA in tumor tissue sample were obtained over the course of HIPEC combined PD1/PDL1 inhibitor conversion treatment will be assessed by high-intensity, next-generation sequencing(NGS) to identify genomic alterations. The assay will performed used AmoyDx® Master Panel(Amoy Diagnostics Co., Xiamen, China), which contains 559 genes for DNA mutation detection and 1813 genes for RNA expression and fusion detection. Data acquired will be analyzed to characterize the association between these genetic elements, clinical response, and durability of responses. There will be prospective groups for the study. Samples will be collected from patients in the prospective cohort who have been treated with HIPEC combined PD1/PDL1 inhibitor at Affiliated Cancer Hospital \& Institute of Guangzhou Medical University under standard of conversion treatment.

Eligibility Criteria:
Inclusion Criteria:

1. Advanced gastric (gastroesophageal junction) adenocarcinoma confirmed by histology;
2. Age 18-75 years, Male or Non-pregnant female
3. Eastern Cooperative Oncology Group(ECOG): 0\~1；
4. Negative for human epidermal growth factor receptor 2(HER-2) by immunocytochemistry or fluorescence in situ hybridization；
5. The presence of gastric cancer peritoneal metastasis is confirmed by laparoscopic exploration, and the PCI≤20；
6. Patients had received HIPEC combined with PD1/PDL1 inhibitor conversion therapy.
7. Signed the Informed Consent Form, and blood and tissue samples can be obtained;

Exclusion Criteria:

1. Other distal metastases besides peritoneal metastases (e.g., liver, lung, pleural, brain, bone metastases, etc.);
2. Other patients who were considered unsuitable for inclusion by the researchers;